Verkubo Tablets 2.5 mg (Vericiguat (unmatured))

Adult dose

1. Adults The recommended starting dose of this medicine is 2.5mg once daily. Take with food. Depending on the patient's tolerability, double the dose approximately every 2 weeks until the target maintenance dose of 10mg once daily is reached. If the patient does not tolerate the medicine well (systolic blood pressure below 90 mmHg or symptomatic hypotension), reduce the dose or discontinue treatment. Do not initiate treatment with this medicine if systolic blood pressure is below 100 mmHg. For patients unable to swallow the tablet whole, this medicine may be crushed and mixed with water immediately before taking it. (See 11. Information for healthcare professionals, 2) Pharmacokinetic information) Missed dose: If a dose is missed, take it as soon as possible on the same day. Do not take this medicine twice on the same day. 2. Older adults No dose adjustment is necessary in older adults. (See 9. Use in older adults and 11. Information for healthcare professionals, 2) Pharmacokinetic information) 3. Patients with renal impairment No dose adjustment is necessary in patients with eGFR≥15mL/min/1.73m2 who are not receiving dialysis. This medicine has not been studied in patients with eGFR<15 mL/min/1.73m2 or in patients receiving dialysis at treatment initiation; therefore, it is not recommended for these patients. (See 11. Information for healthcare professionals, 2) Pharmacokinetic information) 4. Patients with hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. This medicine has not been studied in patients with severe hepatic impairment; therefore, it is not recommended for these patients. (See 11. Information for healthcare professionals, 2) Pharmacokinetic information)

This medication should not be used in pregnant women as it may harm the fetus. Women of childbearing age must confirm pregnancy before taking this medication, and effective contraception must be used during treatment and for one month after discontinuation. Patients with allergies to any components of this medication or who are taking certain other medications should not use it. In particular, it should not be taken by patients taking other soluble guanylate cyclase stimulators or pregnant women, and those with genetic issues such as lactose intolerance should avoid it. Patients with low blood pressure or symptomatic hypotension should use this medication cautiously, as hypotensive symptoms may worsen. Additionally, concomitant use with certain cardiac medications or PDE-5 inhibitors may increase the risk of symptomatic hypotension; hence, combined use is not recommended. Side effects such as dizziness, headache, nausea, vomiting, dyspepsia, and low blood pressure may occur. If these symptoms are severe, immediate consultation with medical personnel is advised. Pregnant or breastfeeding women should not take this medication, and if breastfeeding, it is safest to stop nursing while on this medication. The safety and efficacy for pediatric patients have not yet been established; therefore, its use is not recommended in this population. Elderly patients do not require special dose adjustments, but older patients may be more sensitive to the medication, so caution is needed. In case of overdose, low blood pressure may occur, and immediate medical attention is required. This medication is not removed by hemodialysis, so symptomatic treatment is necessary in cases of overdose.

• Anemia
• nausea
• dyspepsia
• vomiting
• gastroesophageal reflux disease
• dizziness
• headache
• hypotension
• symptomatic hypotension

This medication should be stored in a tightly closed container to protect it from air and moisture. It is important to keep it at a cool temperature between 2°C and 30°C to maintain its effectiveness.

Appearance

White, round, film-coated tablet with a biconvex shape on both sides

Package unit

Domestic use - 14 tablets/box [(14 tablets/blister x 1)]